236 related articles for article (PubMed ID: 22332769)
1. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
2. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
3. Therapy for metastatic RCC--questions remain.
Breau RH; Leibovich BC
Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
[No Abstract] [Full Text] [Related]
4. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Tomita Y
Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
[No Abstract] [Full Text] [Related]
5. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
6. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Wu Y; Zhao Y
Int J Urol; 2011 Jun; 18(6):430-1. PubMed ID: 21599760
[No Abstract] [Full Text] [Related]
7. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Mizutani Y
Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
10. A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
Benincasa E; Conti A; Bossone G; Gallà DA; Gianciotta A; Zuccaro SM; Madaio R
Tumori; 2009; 95(3):403. PubMed ID: 19688987
[No Abstract] [Full Text] [Related]
11. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
12. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
13. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
[No Abstract] [Full Text] [Related]
14. Tilting the AXIS towards therapeutic limits in renal cancer.
Bex A; Haanen J
Lancet; 2011 Dec; 378(9807):1898-900. PubMed ID: 22056245
[No Abstract] [Full Text] [Related]
15. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Larkin J; Gore M
Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
[No Abstract] [Full Text] [Related]
16. [Renal cell carcinoma].
Oya M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
[No Abstract] [Full Text] [Related]
17. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
18. Editorial comment.
Rini BI; Shah SN
Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
[No Abstract] [Full Text] [Related]
19. Editorial comment.
Vaishampayan U
Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
[No Abstract] [Full Text] [Related]
20. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
